| Serplulimab Plus Bevacizumab and Chemotherapy for Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer After First-Line Anti-EGFR Therapy | Capecitabine, Fluorouracil | Phase 2 | Not yet recruiting | China Medical University, China | Nov 20, 2026 |
| A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AML | Azacitidine, Cytarabine | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | Nov 19, 2026 |
| Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML) | Cytarabine | Phase 3 | Not yet recruiting | University Hospital, Toulouse | Nov 19, 2026 |
| A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML) | Cytarabine | Phase 4 | Not yet recruiting | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Nov 19, 2026 |
| HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer | Capecitabine | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | Nov 17, 2026 |
| Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5 | Capecitabine | Phase 3 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Nov 17, 2026 |
| Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer | Fluorouracil | Phase 2 | Not yet recruiting | Damanhour University | Nov 17, 2026 |
| RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma | Capecitabine, Fluorouracil | Phase 2 / Phase 3 | Not yet recruiting | RemeGen Co., Ltd. | Nov 13, 2026 |
| Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling. | Cytarabine | Phase 4 | Recruiting | Liverpool John Moores University | Nov 13, 2026 |
| Sonrotoclax in Combination With Azacitidine for Previously Untreated Higher-risk Myelodysplastic Syndromes | Azacitidine | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | Nov 12, 2026 |
| SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3) | Capecitabine, Fluorouracil | Phase 3 | Not yet recruiting | Fudan University | Nov 12, 2026 |
| QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients | Fluorouracil | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Nov 12, 2026 |
| Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Tegafur | Phase 2 | Recruiting | Beijing Tsinghua Chang Gung Hospital | Nov 12, 2026 |
| A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | Azacitidine | Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | Nov 9, 2026 |
| Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast Cancer | Capecitabine, Fluorouracil | — | Active, not recruiting | Peking Union Medical College Hospital | Nov 9, 2026 |
| GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis | Tegafur | Phase 1 | Not yet recruiting | Ruijin Hospital | Nov 6, 2026 |
| Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer | Capecitabine, Fluorouracil | Phase 3 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | Nov 4, 2026 |
| Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer | Capecitabine | Phase 3 | Not yet recruiting | Zhai Wenlong | Nov 4, 2026 |
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer | Fluorouracil | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | Nov 4, 2026 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Cytarabine | Phase 1 | Not yet recruiting | City of Hope Medical Center | Nov 3, 2026 |
| MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC ) | Cytarabine | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | Oct 29, 2026 |
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 | Azacitidine | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Oct 21, 2026 |
| Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study | Tegafur | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Oct 14, 2026 |
| Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML | Azacitidine | Phase 2 | Not yet recruiting | Rutgers, The State University of New Jersey | Oct 9, 2026 |
| Low Dose Induction for Pediatric Acute Myeloid Leukemia Patients | Cytarabine | Not applicable | Recruiting | Azza Shibl Sayed | Oct 9, 2026 |
| Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer | Tegafur | Phase 2 | Recruiting | Ruijin Hospital | Oct 9, 2026 |
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer | Azacitidine | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | Oct 8, 2026 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Azacitidine, Cytarabine | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | Oct 7, 2026 |
| Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML | Azacitidine | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Sep 18, 2026 |
| A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma | Tegafur | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | Sep 18, 2026 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma | Tegafur | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | Sep 14, 2026 |
| A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression. | Tegafur | Phase 2 | Recruiting | Xijing Hospital | Aug 26, 2026 |
| Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL | Carmustine | Phase 2 | Not yet recruiting | Ruijin Hospital | Aug 19, 2026 |
| Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma | Tegafur | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | Aug 19, 2026 |
| CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. | Carmustine | Phase 2 | Recruiting | Zhejiang Cancer Hospital | Apr 20, 2026 |
| Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas | Carmustine | — | Active, not recruiting | Blokhin's Russian Cancer Research Center | Mar 4, 2026 |
| Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | Carmustine | Phase 2 | Recruiting | Ruijin Hospital | Sep 30, 2025 |
| Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial | Carmustine | Phase 4 | Recruiting | Chinese PLA General Hospital | Aug 3, 2025 |
| A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | Carmustine | Phase 2 | Recruiting | VIVUS LLC | Apr 8, 2025 |
| CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant | Carmustine | Phase 2 | Recruiting | Washington University School of Medicine | Nov 14, 2024 |
| Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive | Carmustine | Phase 2 | Not yet recruiting | Ruijin Hospital | Oct 22, 2024 |
| A Study of RSLV-132 in Females With Sjögren's Disease | RSLV-132 | Phase 2 | Active, not recruiting | Resolve Therapeutics | Jun 4, 2024 |